More layoffs

Quote






I think it will start with the CEO being fired! To save "$1 Billion" his "Fit for Growth" initiative resulted in over 1,000 lost jobs and then lost over $16 Billion in market cap.
 






This place is not what was advertised, so many want to be laid off. Every place has crazy goals, but this place tops them all. When you way overpay for a company/product, and realize the patients aren't there, the panic sets in. Reps are busting their butt, but not making any bonus. If they're not being laid off, then the mass exodus is starting anyway.
 






anonymous said:
This place is not what was advertised, so many want to be laid off. Every place has crazy goals, but this place tops them all. When you way overpay for a company/product, and realize the patients aren't there, the panic sets in. Reps are busting their butt, but not making any bonus. If they're not being laid off, then the mass exodus is starting anyway.
Click to expand...
They treat rare like a primary care. They don't like to listen to suggestions from their tenured reps in this field. There are some cool things about this company. But it's hard to imagine anyone staying long term. Most I've talked to are looking elsewhere.
 






anonymous said:
They treat rare like a primary care. They don't like to listen to suggestions from their tenured reps in this field. There are some cool things about this company. But it's hard to imagine anyone staying long term. Most I've talked to are looking elsewhere.
Click to expand...
We don’t listen because we aren’t interested in which restaurants have compostable drink carriers.
 












Yes, they will be more layoffs, not in our growth divisions. With the recent full take over of Sage, Biogen will continue to pivot away from MS, eventually being out of it, or a very small footprint. MS will get cut deeper as they is not seen as the future of Biogen what so ever.
 






anonymous said:
This place is a fucking train wreck. We haven’t done anything right for seven or eight years now.
Click to expand...
Very late 2016 was the Spinrazza approval and launch in early 2017. The sales growth on that drug early on surprised everyone and it masked a lot of problems that were growing within. You’re right, nothing has really gone right or well since 2017.

If you talk to people who used to work here or been here for years based in Cambridge, they all reference two time periods. 1.) The October 2015 layoffs which gutted many good teams and employees that were the “roll-up your sleeves and get it done” glue-guy types, and led to a further exodus of good talent that following bonuses Feb-April 2016. And 2.) By Mid-2017 there was a noticeable big shift in culture with the aforementioned layoffs & departures and their new hire replacements, many were cut-throat and horrible to work with. Many departments started to allow remote employees in 2017. Every team that started to allow remote had major performance and team cohesiveness problems within 6-12 months.
 






























I am learning this company does not make smart moves. They way overpaid for Sky, and now they're in a panic because...duh...it's rare. No one will be making a bonus.
Then offering to buyout sage. Sure, they have their hand in the cookie jar, but cut your losses. They are in the red of over spending.
Alzheimers MOA is complete crap. Everything needs to be scrapped there. Whatever used to be known as a good company, is so far gone now. Please lay us off.
 






anonymous said:
Very late 2016 was the Spinrazza approval and launch in early 2017. The sales growth on that drug early on surprised everyone and it masked a lot of problems that were growing within. You’re right, nothing has really gone right or well since 2017.

If you talk to people who used to work here or been here for years based in Cambridge, they all reference two time periods. 1.) The October 2015 layoffs which gutted many good teams and employees that were the “roll-up your sleeves and get it done” glue-guy types, and led to a further exodus of good talent that following bonuses Feb-April 2016. And 2.) By Mid-2017 there was a noticeable big shift in culture with the aforementioned layoffs & departures and their new hire replacements, many were cut-throat and horrible to work with. Many departments started to allow remote employees in 2017. Every team that started to allow remote had major performance and team cohesiveness problems within 6-12 months.
Click to expand...
Not true for all teams. It's a global company and hybrid happened organically because of teams located across time zones. Hybrid and multi site teams should be successful with the right leadership. Sounds like your team is lacking that.

Maybe controlling and micromanaging leaders feel like you do but the culture shift was at the top.
 






anonymous said:
Not true for all teams. It's a global company and hybrid happened organically because of teams located across time zones. Hybrid and multi site teams should be successful with the right leadership. Sounds like your team is lacking that.

Maybe controlling and micromanaging leaders feel like you do but the culture shift was at the top.
Click to expand...
That poster’s described experience was commonly felt. Your response is a meaningless word salad. Let me ask you this, is the company better off today than it was 5-6 years ago? Keep in mind the mess of today is the result of how things operated going as far back as 2017 that set things in motion.

In 2019 the company’s revenue was $14.4B, profits were $5.88B and Biogen was #223 on the Fortune 500 list. They were coasting off of what was done several years prior. In 2023 the revenue was $9.8B, profits were $1.1B and #401 on the Fortune 500 list. They also had staff cuts and pipeline failures in 2023. So, with that said, is that level of decline indicative of a well run company from top to bottom over the prior several years? Did the remote work that started in 2017 prove to be fruitful for long-term success for the company?
 






anonymous said:
That poster’s described experience was commonly felt. Your response is a meaningless word salad. Let me ask you this, is the company better off today than it was 5-6 years ago? Keep in mind the mess of today is the result of how things operated going as far back as 2017 that set things in motion.

In 2019 the company’s revenue was $14.4B, profits were $5.88B and Biogen was #223 on the Fortune 500 list. They were coasting off of what was done several years prior. In 2023 the revenue was $9.8B, profits were $1.1B and #401 on the Fortune 500 list. They also had staff cuts and pipeline failures in 2023. So, with that said, is that level of decline indicative of a well run company from top to bottom over the prior several years? Did the remote work that started in 2017 prove to be fruitful for long-term success for the company?
Click to expand...
Explain how a team across 4 time zones benefits from mandatory on-site 5 days when they are not co-located? You make no sense. Your Financials are word salad. The reason for current state is there was no pipeline or strong R&D leadership for the pipeline.
 






So what's the end game? It feels like a long, slow death spiral. I love how we're now talking about buying Sage when, really, what would be best for employees is for a company with more capable leadership to buy Biogen. I know most of us here are in commercial, but it seems like the feeling is the same company-wide. I keep hearing rumors about mass layoffs in R&D this month. When does the Board actually do something? How bad does it have to get? Are we thinking there's a mass exodus after bonus and vesting in Feb?
 






The 'get ready, you will find out more tomorrow' emails went out today, so it might get bloody on Wednesday. Director/Senior Director leaders with teams of people under them heard nothing about what is coming.
 






Jane Grogan, Ph.D., took over Biogen’s research department in the wake of large-scale layoffs. Now, a little more than a year later, she’s making cuts of her own.

The neuro-focused biotech is “making changes” to its research team to “reinvigorate the company's drug discovery capabilities and support long-term sustainable growth,” a Biogen spokesperson told Fierce Biotech via email.

The spokesperson declined to share how many employees will be laid off. The workforce reduction was first reported by Endpoints News after the publication obtained an internal memo sent from Grogan to staff.

Biogen research team hit by layoffs as company shifts resources to external opportunities
 






anonymous said:
So what's the end game? It feels like a long, slow death spiral. I love how we're now talking about buying Sage when, really, what would be best for employees is for a company with more capable leadership to buy Biogen. I know most of us here are in commercial, but it seems like the feeling is the same company-wide. I keep hearing rumors about mass layoffs in R&D this month. When does the Board actually do something? How bad does it have to get? Are we thinking there's a mass exodus after bonus and vesting in Feb?
Click to expand...
Biogen research team hit by layoffs as company shifts resources to external opportunities
 






Top Bottom
Back
Quote